Esperion Therapeutics Inc (ESPR)

11.31
0.43 3.70
NASDAQ : Health Care
Prev Close 11.74
Open 11.69
Day Low/High 11.26 / 11.76
52 Wk Low/High 9.58 / 98.56
Volume 111.19K
Avg Volume 356.50K
Exchange NASDAQ
Shares Outstanding 22.55M
Market Cap 249.67M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

7 Unusual-Volume Stocks That Are About to Break Out

7 Unusual-Volume Stocks That Are About to Break Out

These stocks rising on unusual volume are within range of triggering big breakout trades.

ESPR: Insiders vs. Shorts

ESPR: Insiders vs. Shorts

The most recent short interest data was recently released for the 08/15/2016 settlement date, and Esperion Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 9.69 "days to cover" versus the median component at 5.83. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

It's Time to Bring the Heat

It's Time to Bring the Heat

I'm starting a new periodic feature that will bring you the hottest-trading stocks I see.

These 5 Stocks Are Breaking Out

These 5 Stocks Are Breaking Out

Here's a technical look at how to trade five stocks that look poised to break out and trade higher from current levels.

Commit To Purchase Esperion Therapeutics At $8, Earn 28.2% Annualized Using Options

Commit To Purchase Esperion Therapeutics At $8, Earn 28.2% Annualized Using Options

Investors considering a purchase of Esperion Therapeutics Inc shares, but cautious about paying the going market price of $10.50/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $8 strike, which has a bid at the time of this writing of $1.00.

Esperion Falls on Regulatory Setback for Cholesterol-Lowering Pill

Esperion Falls on Regulatory Setback for Cholesterol-Lowering Pill

Esperion Therapeutics and the U.S. Food and Drug Administration failed to reach agreement on a definitive approval path for the company's cholesterol-lowering pill.

ESPR: Insiders vs. Shorts

ESPR: Insiders vs. Shorts

The most recent short interest data was recently released for the 03/31/2016 settlement date, and Esperion Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 10.33 "days to cover" versus the median component at 5.75. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Commit To Buy Esperion Therapeutics At $13, Earn 23.5% Annualized Using Options

Commit To Buy Esperion Therapeutics At $13, Earn 23.5% Annualized Using Options

Investors eyeing a purchase of Esperion Therapeutics Inc shares, but tentative about paying the going market price of $18.64/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $13 strike, which has a bid at the time of this writing of $1.35.

INVESTOR DEADLINE: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Esperion Therapeutics, Inc.

INVESTOR DEADLINE: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Esperion Therapeutics, Inc.

Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc.

Scott + Scott, LLP Notifies Investors That Monday, March 14, 2016 Is Last Day To File Lead Plaintiff Papers In Esperion Therapeutics (ESPR) Securities Case

Scott + Scott, LLP Notifies Investors That Monday, March 14, 2016 Is Last Day To File Lead Plaintiff Papers In Esperion Therapeutics (ESPR) Securities Case

Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics,...

Scott + Scott, LLP Notifies Investors Of Monday, March 14, 2016 Deadline In Esperion Therapeutics (ESPR) Securities Case

Scott + Scott, LLP Notifies Investors Of Monday, March 14, 2016 Deadline In Esperion Therapeutics (ESPR) Securities Case

Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics,...

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Esperion Therapeutics, Inc.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Esperion Therapeutics, Inc.

Law Office of Brodsky & Smith, LLC announces an investigation of Esperion Therapeutics, Inc.

Scott + Scott, LLP Notifies Investors Of Monday, March 14, 2016 Deadline In Esperion Therapeutics (ESPR) Securities Case

Scott + Scott, LLP Notifies Investors Of Monday, March 14, 2016 Deadline In Esperion Therapeutics (ESPR) Securities Case

Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics,...

ESPR: Insiders vs. Shorts

ESPR: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 02/12/2016 settlement date, and Esperion Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 10.74 "days to cover" versus the median component at 5.27. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Scott + Scott, LLP Reminds Investors Of Monday, March 14, 2016 Deadline To File Lead Plaintiff Papers In Esperion Therapeutics (ESPR) Securities Case

Scott + Scott, LLP Reminds Investors Of Monday, March 14, 2016 Deadline To File Lead Plaintiff Papers In Esperion Therapeutics (ESPR) Securities Case

Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the deadline for filing lead plaintiff papers in the securities lawsuit against Esperion...

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Esperion Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of March 14, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Esperion Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of March 14, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Esperion Therapeutics, Inc.

ESPERION INVESTORS NOTICE: Lieff Cabraser Reminds Investors Of Deadline In Class Action Against Esperion Therapeutics, Inc.

ESPERION INVESTORS NOTICE: Lieff Cabraser Reminds Investors Of Deadline In Class Action Against Esperion Therapeutics, Inc.

The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in securities class litigation brought on behalf of investors who purchased...